HomeCompareGTSVX vs JNJ

GTSVX vs JNJ: Dividend Comparison 2026

GTSVX yields 7.78% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GTSVX wins by $13.4K in total portfolio value
10 years
GTSVX
GTSVX
● Live price
7.78%
Share price
$37.96
Annual div
$2.95
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.5K
Annual income
$1,273.18
Full GTSVX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — GTSVX vs JNJ

📍 GTSVX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGTSVXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GTSVX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GTSVX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GTSVX
Annual income on $10K today (after 15% tax)
$661.21/yr
After 10yr DRIP, annual income (after tax)
$1,082.20/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, GTSVX beats the other by $378.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GTSVX + JNJ for your $10,000?

GTSVX: 50%JNJ: 50%
100% JNJ50/50100% GTSVX
Portfolio after 10yr
$26.7K
Annual income
$1,050.48/yr
Blended yield
3.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GTSVX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GTSVX buys
0
JNJ buys
0
No recent congressional trades found for GTSVX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGTSVXJNJ
Forward yield7.78%3.36%
Annual dividend / share$2.95$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$33.5K$20.0K
Annual income after 10y$1,273.18$827.78
Total dividends collected$10.3K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GTSVX vs JNJ ($10,000, DRIP)

YearGTSVX PortfolioGTSVX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,478$777.90$10,676$355.77+$802.00GTSVX
2$13,116$834.45$11,407$389.39+$1.7KGTSVX
3$14,925$891.15$12,198$426.53+$2.7KGTSVX
4$16,918$947.74$13,056$467.62+$3.9KGTSVX
5$19,106$1,003.98$13,987$513.12+$5.1KGTSVX
6$21,503$1,059.66$14,998$563.56+$6.5KGTSVX
7$24,123$1,114.59$16,098$619.52+$8.0KGTSVX
8$26,980$1,168.59$17,295$681.69+$9.7KGTSVX
9$30,090$1,221.49$18,599$750.82+$11.5KGTSVX
10$33,469$1,273.18$20,022$827.78+$13.4KGTSVX

GTSVX vs JNJ: Complete Analysis 2026

GTSVXStock

The fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of small-capitalization issuers. It invests primarily in equity securities. The principal type of equity security in which the fund invests is common stock. The fund's manager considers an issuer to be a small-capitalization issuer if it has a market capitalization, at the time of purchase, no larger than the largest capitalized issuer included in the Russell 2000® Index.

Full GTSVX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this GTSVX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GTSVX vs SCHDGTSVX vs JEPIGTSVX vs OGTSVX vs KOGTSVX vs MAINGTSVX vs ABBVGTSVX vs MRKGTSVX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.